The global plasma fraction market was valued at approximately USD 32.75 billion in 2023 and is forecasted to reach USD 72.86 billion by 2034, representing a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034.There is a rising demand to create medicine products derived from plasma to treat rabies, tetanus, shock, and trauma. This factor is owing to the growth of the plasma fraction market.
Despite the life-saving benefits of plasma and its derived proteins, the high cost of plasma-derived medicinal products (PDMPs) is hindering market growth. Rising plasma prices have directly affected the sustainability of PDMP production. During the pandemic, many countries experienced shortages of immunoglobulin, leading to rationing for patients with critical illnesses. Even in nations like Germany and the United States, where commercially sourced plasma availability is relatively high, a shortage has been noted due to surging demand for PDMPs. Over the last five years, the cost of plasma per liter has risen by 59.3% in Europe and 40.7% in the United States.
In 2023, North America dominated the plasma fraction market, driven by an increase in plasma exports from the region. The United States is the world’s leading exporter of plasma, accounting for approximately 70% of global plasma supplies. This significant contribution has allowed the U.S. to collect the majority of the world’s plasma for PDMP production, generating a staggering $37 billion in blood product exports in 2023. As global demand for plasma continues to grow, the pressure on the U.S. to extract and export more plasma intensifies.
Europe is anticipated to experience the fastest growth during the forecast period, primarily due to stringent regulations and rising plasma shortages. Many European countries now rely on imports to satisfy their medical needs. Notably, just four countries—Austria, Czechia, Germany, and Hungary—collect over 55% of the total plasma used for manufacturing in Europe.
In July 2024, the European Union implemented new regulations governing the quality and safety standards for substances of human origin intended for human use. This regulation, approved by the European Parliament, will take effect in May 2024.
By type, the immunoglobulins segment held the largest market share in 2023. Plasma-derived immunoglobulins are vital for treating autoimmune inflammatory diseases and play a crucial role in recovery following infections, such as COVID-19. They are often the sole treatment option for rare conditions like primary immunodeficiency.
The coagulation factors segment is expected to grow at the fastest rate during the forecast period, driven by their application in treating blood clotting disorders such as hemophilia and Von Willebrand’s disease.
By application, the hospital segment dominated the plasma fraction market, accounting for the largest share. This dominance is attributed to the use of plasma proteins in treating patients recovering from burns, trauma, animal bites, shock, major surgeries, hepatitis, RH incompatibility, organ transplants, pediatric HIV, and liver conditions.
The retail pharmacy segment is projected to grow at the fastest rate within the plasma fraction market, spurred by an increasing number of human donors providing sufficient plasma supplies. Additionally, a rising number of patients eligible for plasma-derived therapies will boost demand in the retail pharmacy sector.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5304
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/plasma-fraction-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5304
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The sequencing consumables market is experiencing rapid growth, driven by advancements in genetic sequencing technologies and the increasing demand for… Read More
The medical imaging informatics market is experiencing significant growth, driven by advancements in technology and increasing healthcare needs. This dynamic… Read More
In recent years, the integration of Artificial Intelligence (AI) with upstream bioprocessing has proven to be a game-changer for the… Read More
The global cell separation technologies market is experiencing rapid growth, driven by technological advancements, rising demand for immunotherapy and regenerative… Read More
The infertility treatment market has witnessed significant growth, with various segments contributing to its expansion. The global market is estimated… Read More
In the world of healthcare, advancements in technology are acting like superheroes for Electronic Health Records (EHR) systems, taking them… Read More